CAJ | 학술논문

目的探讨非诺贝特对早期糖尿病肾病患者的肾保护作用。方法将84例糖尿病肾病患者随机平均分为对照组和治疗组，对照组进行常规降糖降压治疗，治疗组在此基础上给予非诺贝特治疗，记录比较患者治疗前后血糖、血压、血肌酐(SCr)、血脂和微量白蛋白(mAlb)水平的变化以及核因子-κB (NF-κB)的活性。结果两组患者治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)与治疗前相比较差异均有显著性(P <0.05)；治疗组患者治疗后 FPG、2hPG与对照组相比较差异无显著性(P>0.05)。两组治疗前后及组间 SCr 相相比较差异均无显著性(P>0.05)。对照组患者治疗前后血脂各项指标和 mAlb 水平无明显变化(P >0.05)；治疗组患者治疗后血脂各项指标和mAlb水平与治疗前比差异具有显著性(P <0.05)；治疗组与对照组治疗后血脂各项指标和mAlb水平比较差异均有显著性(P>0.05)。对照组患者治疗前后 NF-κB的水平无明显变化(P >0.05)；而治疗组患者治疗后该水平较治疗前明显下降，且差异有显著性(P <0.05)；两组患者治疗后 NF-κB水平相比较差异具有显著性(P<0.05)。结论非诺贝特能明显改善早期糖尿病肾病患者血脂和 mAlb 水平，降低 NF-κB P65的活性，从而发挥一定的肾功能保护作用。
목적탐토비낙패특대조기당뇨병신병환자적신보호작용。방법장84례당뇨병신병환자수궤평균분위대조조화치료조，대조조진행상규강당강압치료，치료조재차기출상급여비낙패특치료，기록비교환자치료전후혈당、혈압、혈기항(SCr)、혈지화미량백단백(mAlb)수평적변화이급핵인자-κB (NF-κB)적활성。결과량조환자치료후공복혈당(FPG)、찬후2h혈당(2hPG)여치료전상비교차이균유현저성(P <0.05)；치료조환자치료후 FPG、2hPG여대조조상비교차이무현저성(P>0.05)。량조치료전후급조간 SCr 상상비교차이균무현저성(P>0.05)。대조조환자치료전후혈지각항지표화 mAlb 수평무명현변화(P >0.05)；치료조환자치료후혈지각항지표화mAlb수평여치료전비차이구유현저성(P <0.05)；치료조여대조조치료후혈지각항지표화mAlb수평비교차이균유현저성(P>0.05)。대조조환자치료전후 NF-κB적수평무명현변화(P >0.05)；이치료조환자치료후해수평교치료전명현하강，차차이유현저성(P <0.05)；량조환자치료후 NF-κB수평상비교차이구유현저성(P<0.05)。결론비낙패특능명현개선조기당뇨병신병환자혈지화 mAlb 수평，강저 NF-κB P65적활성，종이발휘일정적신공능보호작용。
Obj ective]To explore the renal protective effect of fenofibrate on patients with early diabetic nephropa-thy.[Methods]Totally 84 patients with diabetic nephropathy were randomly divided into control group and treatment group.The control group was treated with conventional blood glucose and pressure-lowering,while the treatment group was treated with fenofibrate based on the treatment of control group.The changes of blood glucose,blood pressure,ser-um creatinine(CCr),and urine creatinine,blood lipids,microalbumin and the activity of nuclear factor-κB(NF-κB)before and after treatment were recorded and compared.[Results]There were significant differences in fasting blood glucose (FPG)and postprandial 2h blood glucose(2hPG)of two groups between before and after treatment(P<0.05).There was no significant difference in FPG and 2hPG after treatment between treatment group and control group(P>0.05). There was no significant difference in CCr between two groups or before and after treatment(P>0.05).There was no significant difference in blood lipids and microalbumin of control group between before and after treatment(P>0.05). There was significant difference in blood lipids and microalbumin of treatment group between before and after treatment (P<0.05).There was significant difference in blood lipids and microalbumin after treatment between treatment group and control group(P<0.05).There was no significant difference in NF-κB of control group between before and after treatment(P>0.05).Compared with before treatment,NF-κB in treatment group after treatment was obviously de-creased,and there was significant difference(P<0.05).There was significant difference in NF-κB after treatment be-tween two groups(P<0.05).[Conclusion]Fenofibrate can obviously improve blood lipids and microalbumin,and de-crease the activity of NF-κB P6 5 in patients with early diabetic nephropathy.Therefore,it has renal protective effect.